RTP Mobile Logo
Challenging Cases in Non-Hodgkin Lymphoma: Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty
Released July 2013

Video excerpts from the third in a series of 6 integrated symposia held at the 2013 ONS Annual Congress. Featuring perspectives from Dr Andrew M Evens, Ms Amy Goodrich, Ms Mollie Moran and Dr Lauren C Pinter-Brown. (Video Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma (NHL).

    Taken together, it is estimated that approximately 148,040 new lymphoid and myeloid cancer cases were identified in the United States in the year 2012, and 54,380 individuals died from these diseases. Of importance, there are currently more than 50 drug products labeled for use in the management of hematologic cancers with more than 60 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors, and the dynamic therapeutic NHL environment dictates that all pivotal members of the oncology/hematology care team be able to appropriately identify the benefits and risks of the plethora of emerging treatment options.

    These video proceedings from the third part of a 6-part integrated CNE curriculum originally held at the 2013 ONS Annual Congress feature discussions with leading NHL investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario. By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with NHL.


    • Identify the unique risks and benefits associated with commonly used therapeutic approaches for patients with newly diagnosed or relapsed/refractory NHL/chronic lymphocytic leukemia (CLL) to facilitate appropriate patient counseling.
    • Formulate supportive care strategies to manage the side effects associated with these interventions to maximize patient quality of life while minimizing the potential for treatment discontinuation.
    • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with NHL/CLL to optimize clinical and quality-of-life outcomes.
    • Recall ongoing trials of investigational approaches and agents in NHL and CLL, and consent and refer patients for study participation.

    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CNE activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Andrew M Evens, DO, MSc
    Associate Professor of Medicine
    Deputy Director for Clinical and Translational Research
    CRO Medical Director
    UMass Memorial Cancer Center
    Division of Hematology/Oncology
    Director, Lymphoma Program
    The University of Massachusetts Medical School
    Worcester, Massachusetts

    Advisory Committee: Millennium: The Takeda Oncology Company, Seattle Genetics, Spectrum Pharmaceuticals Inc; Contracted Research: Millennium: The Takeda Oncology Company, ZIOPHARM Oncology Inc.

    Amy Goodrich, CRNP-AC
    Nurse Practitioner
    Johns Hopkins Kimmel Cancer Center
    Baltimore, Maryland

    No real or apparent conflicts of interest to report.

    Mollie Moran, MSN, CNP, AOCNP
    The James Cancer Hospital at The Ohio State University
    Columbus, Ohio

    No real or apparent conflicts of interest to report.

    Lauren C Pinter-Brown, MD
    Director, UCLA Lymphoma Program
    Clinical Professor of Medicine
    Geffen School of Medicine at UCLA
    Los Angeles, California

    Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec and Teva Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WiFi is recommended for best performance):